ObsEva
Chemin des Aulx, 12
1228 Plan-les-Ouates
Geneva
Website: http://www.obseva.com/
Email: delphine.renaud@obseva.ch
102 articles about ObsEva
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
ObsEva, based in Geneva, Switzerland and Boston, Massachusetts, announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.
-
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12/9/2019
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids.
-
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
10/31/2019
ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.
-
BioSpace Movers and Shakers: July 3
7/3/2019
Biotech and pharma companies strengthen their executive leadership and board positions. -
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
-
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
10/28/2018
Linzagolix overall efficacy and safety maintained or improved at week 24
-
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
10/9/2018
ObsEva SA today announced that IMPLANT 2 Phase 3 clinical data of its novel, oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF were presented at the 74th annual meeting ofthe American Society of Reproductive Medicine (ASRM), taking place in Denver, Colorado, October 6-10, 2018.
-
Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.
-
ObsEva Sa highlighted a data point from a late-stage trial that showed its fertility treatment nolasiban was successful in improving the pregnancy rate of some women following in vitro fertilization.
-
Dr. Ernest Loumaye, CEO Of ObsEva SA Returns to Work Following a Personal Leave for Medical Reasons
2/1/2018
Dr. Ernest Loumaye extends his gratitude to Dr Frank Verwiel and the Office of the CEO for overseeing the operations of the Company during his absence.
-
The 2017 Biotech IPO Winners and Losers
12/21/2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs. -
ObsEva Initiates PROLONG, the Phase IIa Clinical Trial of OBE022 in Preterm Labor
12/5/2017
The PROLONG trial is the first clinical trial of OBE022 in pregnant women presenting with spontaneous preterm labor at gestational ages between 24 and 34 weeks.
-
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
11/14/2017
Net loss for the third quarter of 2017 was $17.0 million, or $0.59 per basic and diluted share.
-
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase IIb Clinical Trial of OBE2109 for the Treatment of Endometriosis
11/7/2017
Approximately 330 patients are expected to be randomized in the EDELWEISS clinical trial, and primary endpoint efficacy results continue to be anticipated in mid-2018.
-
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
10/31/2017
Management will host an investment community conference call at 8:00 a.m. ET.
-
ObsEva Announces $60 Million Private Placement With Existing And New Investors
10/10/2017
-
ObsEva Announces Presentation Related To Its PGF2alpha Receptor Antagonist At ACCP 2017 Annual Meeting
9/11/2017
-
ObsEva Announces The Completion Of Patient Recruitment In The IMPLANT2 Phase III Clinical Trial In Assisted Reproductive Technology Ahead Of Schedule
9/6/2017
-
ObsEva Reports Second Quarter 2017 Financial Results And Provides Business Update
8/16/2017